Results 121 to 130 of about 419,003 (365)

MRI in liver cirrhosis

open access: yesPortal Hypertension & Cirrhosis, 2022
Liver magnetic resonance imaging (MRI) has seen a massive increase in its use over the last decades. Since its first description in the early 1980s, contrast‐enhanced MRI is now the gold standard for the diagnosis of hepatocellular cancer in patients ...
Osama Alzoubi   +5 more
doaj   +1 more source

Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review

open access: yesInternational Journal of Molecular Sciences, 2019
Almost all patients with hepatocellular carcinoma (HCC), a major type of primary liver cancer, also have liver cirrhosis, the severity of which hampers effective treatment for HCC despite recent progress in the efficacy of anticancer drugs for advanced ...
T. Kanda   +4 more
semanticscholar   +1 more source

Risk Prediction Models for Post‐Operative Mortality in Patients With Cirrhosis

open access: yesHepatology, 2020
Patients with cirrhosis are at increased risk of postoperative mortality. Currently available tools to predict postoperative risk are suboptimally calibrated and do not account for surgery type.
N. Mahmud   +9 more
semanticscholar   +1 more source

Symptom Domain Groups of the Patient-Reported Outcomes Measurement Information System Tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis [PDF]

open access: yes, 2017
Background Patient-Reported Outcomes Measurement Information System (PROMIS) tools can identify health-related quality of life (HRQOL) domains that could differentially affect disease progression.
Bajaj, Jasmohan S.   +14 more
core   +2 more sources

Asprosin‐FABP5 Interaction Modulates Mitochondrial Fatty Acid Oxidation through PPARα Contributing to MASLD Development

open access: yesAdvanced Science, EarlyView.
Aided by FABP5, abnormally elevated asprosin in hepatocytes enters the nucleus, targets and inhibits PPARα binding to the CPT1A promoter, thereby suppressing FAO. Circulating asprosin exacerbates insulin resistance, collectively driving MASLD progression.
Yuan‐Yuan Yu   +13 more
wiley   +1 more source

Anatomical Structure Segmentation in Liver MRI Images [PDF]

open access: yesarXiv, 2012
Segmentation of medical images is a challenging task owing to their complexity. A standard segmentation problem within Magnetic Resonance Imaging (MRI) is the task of labeling voxels according to their tissue type. Image segmentation provides volumetric quantification of liver area and thus helps in the diagnosis of disorders, such as Hepatitis ...
arxiv  

A Spatially Discrete Approximation to Log-Gaussian Cox Processes for Modelling Aggregated Disease Count Data [PDF]

open access: yes, 2019
In this paper, we develop a computationally efficient discrete approximation to log-Gaussian Cox process (LGCP) models for the analysis of spatially aggregated disease count data. Our approach overcomes an inherent limitation of spatial models based on Markov structures, namely that each such model is tied to a specific partition of the study area, and
arxiv   +1 more source

Systemic inflammation in decompensated cirrhosis: Characterization and role in acute‐on‐chronic liver failure

open access: yesHepatology, 2016
Acute‐on‐chronic liver failure (ACLF) in cirrhosis is characterized by acute decompensation (AD), organ failure(s), and high short‐term mortality. Recently, we have proposed (systemic inflammation [SI] hypothesis) that ACLF is the expression of an acute ...
J. Clària   +27 more
semanticscholar   +1 more source

Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites [PDF]

open access: yes, 1993
Torasemide is a new loop diuretic with a longer half-life and longer action than furosemide in healthy subjects. In order to evaluate the pharmacodynamic effects, single oral doses of furosemide (80 mg) and torasemide (20 mg), which were equipotent in ...
Bertheau-Reitha, Ute   +4 more
core   +1 more source

Autocrine GDF10 Inhibits Hepatic Stellate Cell Activation via BMPR2/ALK3 Receptor to Prevent Liver Fibrosis

open access: yesAdvanced Science, EarlyView.
Liver fibrosis is a growing global health burden with no specific treatment. HSC activation is the predominant driver of liver fibrogenesis and the current focus in antifibrotic drug discovery. This study identifies autocrine GDF10 activates BMPR2/ALK3‐SMAD1/5/8‐SMAD7 pathway to counteract the TGF‐β‐SMAD2/3 pathway in HSCs, thereby inhibiting HSC ...
Yinliang Zhang   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy